contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


recap-on-index-pharmaceuticals-and-update-on-pk-results-with-cobitolimod

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Flerie är en aktiv långsiktig life science-investerare med fokus på bioteknik- och läkemedelsinvesteringar globalt. Bolaget är baserat i Stockholm och London, och förvaltar en portfölj med investeringar i Europa, Israel och USA. Huvudfokus ligger på att förse organisationer som främst verkar inom läkemedelsutveckling, med tjänster och resurser. Flerie grundades 2011 och har sitt huvudkontor i Stockholm.

Flerie

Interview with CEO Jenny Sundqvist and CDO Dr. Eva Arlander - Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.

Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
CEO Jenny Sundqvist gave a very confident impression of why the Conclude phase lll study with Cobitolimod were delayed, how they will speed up the process and what potential triggers to look for in Q4-2023.&nbsp;Further the CEO confirmed earlier estimates for growth in the total addressable UC market.
CDO Dr. Eva Arlander deep dived into the recently announced outcome of the PK-study with Cobitolimod 500 mg dose and how they will use positive data going forward.
Listen to the interview: <a title="https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod" contenteditable="false" href="https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod">https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod</a>
Disclaimer:
HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup&nbsp;09:35 AM 03-29-2023.

HC Andersen Capital

Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.

Börs och träning

Saab

Bittium

W5 Solutions

Scandinavian Astor Group

MilDef Group

INVISIO

Argo Defence Group

Europeisk försvarssektor: Långsiktig återupprustning driver fundamentala värden, men aggressiva värderingar tvingar fram selektivitet

Finansiella nyckeltal: EV/EBIT, EV/EBITA, EV/EBITDA och EV/Sales

Vikten av att tänka själv

Guldlock i euroområdet?